Association of GLP-1 Receptor Agonist Use with Kidney and Cardiovascular Outcomes in Stable Kidney Transplant Recipients
Name
jung-emmajung-meng-eecs-2025-thesis.pdf
Description
Thesis PDF
Size
7.33 MB
Format
Adobe PDF
Checksum (MD5)
6db722045fcdbcac379b6ccc4a7d2560
Author(s)
Jung, Emma Yejoo
Advisor(s)
Rinard, Martin
Date Issued
May 2025
Publisher
Massachusetts Institute of Technology
Abstract
Recent surges in the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown promise in reducing cardiovascular events and improving kidney function in patients with type 2 diabetes. Due to these hopeful improvements, kidney transplant recipients (KTRs) have started using GLP-1RA. However, their effects in KTRs remain largely unstudied in clinical studies. This thesis uses a large-scale Electronic Health Record (EHR) database to perform a retrospective cohort analysis to study the association between GLP-1RA use and kidney and cardiovascular outcomes amongst stable KTRs. Primary outcomes include all-cause mortality, major adverse kidney events (MAKE), and major adverse cardiac events (MACE). Among stable KTRs, GLP-1RA users show reduced risk for all-cause mortality (adjusted hazard ratio [aHR]: 0.45; 95% confidence interval [CI]: 0.32-0.62) and MAKE (aHR: 0.69; 95% CI: 0.58-0.81), but no significant difference for MACE (aHR: 0.84; 95% CI: 0.67-1.05). In addition, users show increased risk for irritable bowel syndrome (IBS) (aHR: 2.11; 95% CI: 1.07-4.15) and urinary tract infection (UTI) (aHR: 1.53; 95% CI: 1.27-1.85). These results indicate the potential of GLP-1RA to reduce mortality and adverse kidney outcomes and increase IBS and UTI in KTRs.
MIT Department
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Terms of Use
In Copyright - Educational Use Permitted
Copyright retained by author(s)
Persistent DSpace Link
